GenomeDx Biosciences and Astellas announced a collaboration to apply genomic tumor profiling using GenomeDx’s Decipher Classifier and Decipher GRID as a potential aid in identifying prostate cancer patients undergoing active surveillance who may benefit from treatment with enzalutamide (Xtandi).
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
